Legal Status This site displays a prototype of a “Web 2.0” version of the daily
Federal Register. It is not an official legal edition of the Federal
Register, and does not replace the official print version or the official
electronic version on GPO’s govinfo.gov.

The documents posted on this site are XML renditions of published Federal
Register documents. Each document posted on the site includes a link to the
corresponding official PDF file on govinfo.gov. This prototype edition of the
daily Federal Register on FederalRegister.gov will remain an unofficial
informational resource until the Administrative Committee of the Federal
Register (ACFR) issues a regulation granting it official legal status.
For complete information about, and access to, our official publications
and services, go to About the Federal Register on NARA's archives.gov.

The OFR/GPO partnership is committed to presenting accurate and reliable
regulatory information on FederalRegister.gov with the objective of
establishing the XML-based Federal Register as an ACFR-sanctioned
publication in the future. While every effort has been made to ensure that
the material on FederalRegister.gov is accurately displayed, consistent with
the official SGML-based PDF version on govinfo.gov, those relying on it for
legal research should verify their results against an official edition of
the Federal Register. Until the ACFR grants it official status, the XML
rendition of the daily Federal Register on FederalRegister.gov does not
provide legal notice to the public or judicial notice to the courts.

Legal Status

Notice

Request for Steering Committee Nominations

A Notice by the Reagan-Udall Foundation for the Food and Drug Administration on 08/06/2015

• 1.

1.

• Document Details Published Content - Document Details Agency Reagan-Udall Foundation for the Food and Drug Administration Agency/Docket Number BAC 416404 Document Citation 80 FR 47006 Document Number 2015-19285 Document Type Notice Pages 47006-47007
  (2 pages) Publication Date 08/06/2015 Published Content - Document Details

• PDF Official Content

  • View printed version (PDF) Official Content

• Document Details Published Content - Document Details Agency Reagan-Udall Foundation for the Food and Drug Administration Agency/Docket Number BAC 416404 Document Citation 80 FR 47006 Document Number 2015-19285 Document Type Notice Pages 47006-47007
  (2 pages) Publication Date 08/06/2015 Published Content - Document Details

• Document Dates Published Content - Document Dates Comments Close 09/04/2015 Dates Text All nominations must be submitted to the Reagan-Udall Foundation for the FDA by Friday, September 4, 2015. The BD4P Steering Committee members will be selected by the Reagan-Udall Foundation for the FDA's Board of Directors; those selected will be notified by September 30 regarding the Board's decision. See the SUPPLEMENTARY INFORMATION section for Steering Committee responsibilities, selection criteria and nomination instructions. Published Content - Document Dates

• Table of Contents Enhanced Content - Table of Contents This table of contents is a navigational tool, processed from the
  headings within the legal text of Federal Register documents.
  This repetition of headings to form internal navigation links
  has no substantive legal effect.

  • ACTION:
  • SUMMARY:
  • DATES:
  • ADDRESSES:
  • FOR FURTHER INFORMATION CONTACT:
  • SUPPLEMENTARY INFORMATION:
  • I. Background
  • II. BD4P Steering Committee Roles and Responsibilities
  • III. BD4P Steering Committee Positions and Selection Criteria
  • IV. Terms of Service
  • V. Nomination Instructions Enhanced Content - Table of Contents

• Related Documents Enhanced Content - Related Documents FederalRegister.gov uses the agency dockets published with the document to display related documents.

| BAC 416404
(10 Documents) | | | |
| --- | | | |
| Date | | Action | Title |
| | 2016-04-14 | Notice of annual meeting. | Annual Public Meeting |
| | 2015-08-06 | Request for nominations to the Steering Committee for the Foundation's Big Data for Patients (BD4P) Program. | Request for Steering Committee Nominations |
| | 2015-07-30 | Request for nominations to the Steering Committee for the Foundation's PredicTox project. | Request for Steering Committee Nominations |
| | 2015-05-08 | Request for nominations to the Scientific Advisory Committee for the Foundation's Innovation in Medical Evidence Development and Surveillance (IMEDS) program. | Request for Scientific Advisory Committee Nominations |
| | 2015-04-21 | Notice of annual meeting. | Annual Public Meeting; Reagan-Udall Foundation for the Food and Drug Administration |
| | 2014-04-25 | Notice of annual meeting; correction. | Annual Public Meeting; Correction |
| | 2014-04-03 | Notice of annual meeting. | Annual Public Meeting |
| | 2013-04-23 | Request for nominations to the Steering Committee for the Foundation's Innovation in Medical Evidence Development and Surveillance program. | Request for Steering Committee Nominations |
| | 2013-04-23 | Notice of annual meeting. | Annual Public Meeting |
| | 2012-05-04 | Notice of annual meeting. | Annual Public Meeting |

Enhanced Content - Related Documents

• Public Comments Enhanced Content - Public Comments Comments are no longer being accepted. See DATES for details.

Enhanced Content - Public Comments
- Regulations.gov Data Enhanced Content - Regulations.gov Data Additional information is not currently available for this document.

Enhanced Content - Regulations.gov Data

- Sharing Enhanced Content - Sharing Shorter Document URL https://www.federalregister.gov/d/2015-19285 Email Email this document to a friend Enhanced Content - Sharing

• Print Enhanced Content - Print
  • Print this document Enhanced Content - Print
• Document Statistics Enhanced Content - Document Statistics Document page views are updated periodically throughout the day and are cumulative counts for this document. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.

Page views 350
as of
03/14/2026 at 2:15 pm EDT Enhanced Content - Document Statistics
- Other Formats Enhanced Content - Other Formats This document is also available in the following formats:

JSON Normalized attributes and metadata XML Original full text XML MODS Government Publishing Office metadata More information and documentation can be found in our developer tools pages.

Enhanced Content - Other Formats
- Public Inspection Public Inspection This PDF is FR Doc. 2015-19285 as it appeared on Public Inspection on
08/05/2015 at 8:45 am.

If you are using public inspection listings for legal research, you
should verify the contents of the documents against a final, official
edition of the Federal Register. Only official editions of the
Federal Register provide legal notice of publication to the public and judicial notice
to the courts under 44 U.S.C. 1503 & 1507. Learn more here.

Public Inspection
Published Document: 2015-19285 (80 FR 47006) This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Document Headings Document headings vary by document type but may contain
the following:

1. the agency or agencies that issued and signed a document
2. the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to
3. the agency docket number / agency internal file number
4. the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details.

Reagan-Udall Foundation for the Food and Drug Administration

1. [BAC 416404]

ACTION:

Request for nominations to the Steering Committee for the Foundation's Big Data for Patients (BD4P) Program.

SUMMARY:

The Reagan-Udall Foundation (RUF) for the Food and Drug Administration (FDA), which was created by Title VI of the Food and Drug Amendments of 2007, is requesting nominations for its Big Data for Patients (BD4P) Steering Committee. The Steering Committee will provide oversight and guidance for the BD4P program, and will report to the Reagan-Udall Foundation for the FDA's Board of Directors.

DATES:

All nominations must be submitted to the Reagan-Udall Foundation for the FDA by Friday, September 4, 2015. The BD4P Steering Committee members will be selected by the Reagan-Udall Foundation for the FDA's Board of Directors; those selected will be notified by September 30 regarding the Board's decision. See the SUPPLEMENTARY INFORMATION section for Steering Committee responsibilities, selection criteria and nomination instructions.

ADDRESSES:

The Reagan-Udall Foundation for the FDA is located at 1025 Connecticut Ave. NW., Suite 1000, Washington, DC 20036.

FOR FURTHER INFORMATION CONTACT:

Questions should be sent to The Reagan-Udall Foundation for the FDA, 202-828-1205, BD4P@ReaganUdall.org.

SUPPLEMENTARY INFORMATION:

I. Background

The Reagan-Udall Foundation for the FDA (the Foundation) is an independent ( printed page 47007) 501(c)(3) not-for-profit organization created by Congress to advance the mission of FDA to modernize medical, veterinary, food, food ingredient, and cosmetic product development; accelerate innovation; and enhance product safety. The Foundation acts as a neutral third party to establish novel, scientific collaborations. With the ultimate goal of improving public health, the Foundation provides a unique opportunity for different sectors (FDA, patient groups, academia, other government entities, and industry) to work together in a transparent way to create exciting new research projects to advance regulatory science.

Big Data for Patients (BD4P), a new program led by the Foundation, will bring together multiple stakeholder groups to leverage collective knowledge, technical expertise, funding, and other resources, to create a state-of-the-art patient training program and online community focused on the opportunities and challenges posed by Big Data.

BD4P will empower patients and advocates with the language and concepts of data science, as well as critical appraisal skills, so they can effectively and actively participate in health research involving Big Data. Given the high profile of health research and initiatives using Big Data, combined with the growing efforts to make healthcare and medical research more patient-centered, it is critical that patients have a voice and active role in this work. It is still not completely understood how Big Data research will impact patient health care and medical decision making. BD4P presents an opportunity to ensure that patients are adequately informed and prepared to participate in this work, rather than being left out or left behind.

Development of the program will be a fully collaborative process, with patients and key stakeholders involved in shaping the program every step of the way—from prioritizing topics for program content and input on program design, to actually taking the training program and providing feedback to evaluate the program and make improvements. We will ensure that the focus is not only on the impact of Big Data on patients, but also the impact that patients can have on Big Data research. For additional information on the BD4P program, visit the Reagan-Udall Foundation Web site: http://bit.ly/​1HkhSOq.

II. BD4P Steering Committee Roles and Responsibilities

The BD4P Steering Committee will provide guidance on the operation of the BD4P program, in conjunction with the RUF Board, project staff, and others. The Steering Committee will provide overall programmatic oversight to ensure a focus on the long-term vision of the program.

The BD4P Steering Committee will be charged with several responsibilities, including:

• Reviewing and approving the BD4P Program Charter
• Monitoring adherence to the BD4P Program mission and operational principles in the Charter
• Developing metrics and evaluating the project at various milestones
• Reviewing and approving the BD4P Program Development Plan, including program curriculum, stakeholder engagement plan, and long-term sustainability plan.

• Reviewing partnership and collaboration proposals submitted to the project team
  The BD4P Steering Committee Chair must be able to complete additional responsibilities, including:

• Defining the BD4P Steering Committee's meeting agendas and facilitating those meetings

• Recommending for termination, as necessary, any BD4P Steering Committee members demonstrating dereliction of duties as specified in the BD4P Charter

• Other responsibilities as required upon implementation of BD4P program
  A full list of BD4P Steering Committee responsibilities, as well as responsibilities of the Chair, may be found on the Reagan-Udall Foundation Web site: http://bit.ly/​1KEoNTN.

III. BD4P Steering Committee Positions and Selection Criteria

RUF is seeking nominations for 7 voting members of the BD4P Steering Committee, comprised of the following 5 categories:

• Patient Advocate: 3 members
• Pharmaceutical sector: 1 member
• Technology sector: 1 member
• Academia/Research Institute: 1 member
• At Large: 1 member The BD4P Steering Committee will also have 1 member from the FDA (appointed by the FDA), 1 member from the National Institutes of Health (appointed by the National Institutes of Health), and 1 member from the Patient Centered Outcomes Research Institute (appointed by PCORI). These 3 individuals will be non-voting members.

Nominees for the voting positions will be evaluated by the RUF Board based on the following required criteria for each of the 7 positions:

• Ability to complete Steering Committee responsibilities, listed above
• Currently employed by/volunteering for stakeholder field (e.g., pharmaceutical, academia, patient advocate, etc.) with several years of relevant experience
• Leading expert in their relevant field (based on position, publications, or other experience)
• Working knowledge of at least one of the following areas: Adult education, data sharing, data science, health informatics, learning health care systems, partnerships, patient advocacy, patient engagement, patient-centered/patient-focused drug development, patient-centered outcomes research, patient reported outcomes, precision medicine, science/health communication.
• Prior experience serving on a related or similar governance body
• Understanding of the landscape and the impact on the stakeholder group they are representing with their seat

IV. Terms of Service

• The BD4P Steering Committee meets in-person at least twice per year, with teleconferences in between meetings as deemed necessary by the Chair
• Members will serve two or three year, staggered terms, as determined by the RUF Board
• Members do not receive compensation from RUF
• Members can be reimbursed by RUF for actual and reasonable expenses incurred in support of BD4P in accordance with applicable law and their specific institutional policies
• Members are subject to the BD4P Conflict of Interest policies (additional information can be accessed on the Reagan-Udall Foundation Web site at: http://bit.ly/​1KEoNTN.
• V. Nomination Instructions
• The nomination form can be accessed on the Reagan-Udall Foundation Web site: http://bit.ly/​1KEoNTN
• Individuals may be nominated for 1 or more of the 5 stakeholder categories
• Individuals may nominate themselves or others
• The nomination deadline is September 4, 2015. Dated: July 31, 2015.

Jane Reese-Coulbourne,

Executive Director, Reagan-Udall Foundation for the FDA.

[FR Doc. 2015-19285 Filed 8-5-15; 8:45 am]

BILLING CODE 4164-04-P

Published Document: 2015-19285 (80 FR 47006)